{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 328,
  "pageCount": 415,
  "prevPage": 327,
  "nextPage": 329,
  "slideType": "quote_slide",
  "function": "cite_precedent",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a Q&A transcript format to support the thesis that the competitor product is unnecessary or inferior.",
  "elementsJson": [
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/328",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-328",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Trial investigator #6 stated that regular diazoxide suspension is “always going to be better” than Vykat tablets and stated the formulations are freely substitutable",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2b2-2b5e60f20635",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.86,
        "x": 0.07,
        "y": 0.35
      },
      "kind": "paragraph",
      "text": "Generic liquid diazoxide is “always going to be better” than Vykat tablet; no need to give liquid 2-3X a day for PWS",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b713346-6b78-4212-bafa-8e6f92eb0fee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.86,
        "x": 0.07,
        "y": 0.4
      },
      "kind": "quote",
      "text": "Q: “It sounds like you think that from a pharmacokinetic clinical standpoint, the oral and the DCCR are equivalent; it's the same ingredient, diazoxide, just a different formulation.”\nA: “Yeah, a suspension is always going to be better. And I didn't appreciate it was going to be so expensive.”\nQ: “But you think they're freely interchangeable, as a researcher?”\nA: “Yeah, they should be. And for Prader-Willi, I don't think you'd need to worry so much about titrating it to a certain level and things, because it's not the sugars we're worried about, it's just being able to dampen the hyperphagia response. I think even if, say, they were on the same oral suspension and you were worried about peak levels or whatever, you still wouldn't really need to give it two to three times daily, I don't think, because it's a different —”\nQ: “You think once a day oral suspension is probably sufficient?”\nA: “Yeah, I would have thought so. I'd say, you might need to take it to a dose and then do it. But I would have thought that would be better than a once-daily tablet...” - Trial investigator, pediatric endocrinologist",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0b5a993-a828-422f-881f-90f43db54edb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“Yeah, they should be. And for Prader-Willi, I don't think you'd need to worry so much about titrating it to a certain level and things, because it's not the sugars we're worried about, it's just being able to dampen the hyperphagia response. I think even if, say, they were on the same oral suspension and you were worried about peak levels or whatever, you still wouldn't really need to give it two to three times daily, I don't think, because it's a different —” “Yeah, I would have thought so. I'd say, you might need to take it to a dose and then do it. But I would have thought that would be better than a once-daily tablet.” — Trial investigator, pediatric endocrinologist",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2b2-2dffba15c016",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fcece83b-870e-466f-9e00-0d05a1edf3ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Trial investigator #6 stated that regular diazoxide suspension is “always going to be better” than Vykat tablets and stated the formulations are freely substitutable",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc83c3c7-9b3c-432f-ad32-6c3ca20621fc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}